In today's context of increasing attention to targeted anti-tumor drugs, the Laos Dabear version of Encorafenib, with its compliant production background and reliable cost-effectiveness, has become one of the realistic options for many patients seeking BRAF mutation treatment regimens.
How much does the Laos Dabear version of Encorafenib cost?
The Laos Dabear version of Encorafenib is available in a specification of 75mg*42 capsules/box, priced at approximately $590. The specific price may be affected by various factors and should be based on the actual selling price.
Pharmacological mechanism of action of Encorafenib and advantages of combination therapy
Encorafenib is a small molecule kinase inhibitor with very precise targeting. In cell-free in vitro assays, the half-maximal inhibitory concentration (IC50) against BRAF V600E mutant kinase is 0.35 nM, and the IC50 against wild-type BRAF and CRAF is 0.47 nM and 0.3 nM, respectively. Mutation of the BRAF gene, such as V600E, leads to constitutive activation of BRAF kinase, continuously transmitting proliferative signals downstream, thereby stimulating abnormal tumor cell growth. In addition to the BRAF target, at clinically achievable concentrations (≤0.9 μM), encorafenib can also bind to and inhibit several other kinases, including JNK1, JNK2, JNK3, LIMK1, LIMK2, MEK4, and STK36, but the significance of these off-target effects is not fully understood. At the cellular level, encorafenib inhibits the in vitro growth of human tumor cell lines expressing BRAF V600E, V600D, and V600K mutations. Furthermore, in mouse xenograft models implanted with BRAF V600E mutant human tumor cells, encorafenib monotherapy induced inhibition of the RAF/MEK/ERK signaling pathway and resulted in significant tumor regression. Notably, the combination of encorafenib and binimetinib (another MEK inhibitor) simultaneously blocks two different kinase nodes in the RAS/RAF/MEK/ERK pathway. Compared with monotherapy, the combination shows stronger anti-proliferative activity in BRAF mutation-positive cells in vitro, more significant anti-tumor effects in animal models, and can significantly delay the emergence of drug resistance, which is key to successful clinical treatment.
Pharmacokinetic characteristics and pharmacotoxicological findings of Encorafenib
The pharmacokinetics of encorafenib have been studied in healthy subjects and patients with solid tumors, including those with advanced melanoma harboring BRAF V600E/V600K mutations. Following a single oral dose ranging from 50 to 700 mg, systemic exposure is proportional to dose; however, with once-daily dosing, exposure increases less than dose-proportionally over the 50 to 800 mg range. Steady state is achieved in approximately 15 days, with steady-state concentrations approximately 50% lower than on Day 1; inter-individual variability (CV%) ranges from 12% to 69%. Absorption: median time to peak concentration (Tmax) is 2 hours after oral administration, with at least 86% of the dose absorbed. A high-fat, high-calorie meal reduces peak concentration (Cmax) of a 100 mg dose by 36% but has no effect on total exposure (AUC). Distribution: in vitro plasma protein binding is 86%, blood-to-plasma concentration ratio is 0.58, and geometric mean volume of distribution is 164 L. Elimination: mean terminal half-life is 3.5 hours, and apparent clearance increases from 14 L/h on Day 1 to 32 L/h at steady state. Metabolism is primarily via CYP3A4 (83%), with CYP2C19 (16%) and CYP2D6 (1%) involved. Excretion: after a single oral dose of radiolabeled drug, 47% is recovered in feces (5% as parent drug) and 47% in urine (2% as parent drug). Pharmacotoxicology: carcinogenicity studies of encorafenib have not been conducted; however, bacterial reverse mutation, mammalian cell chromosome aberration, and rat bone marrow micronucleus tests showed no genotoxicity. In animal fertility studies, rats at doses 13 times the human exposure level showed decreased testicular and epididymal weights, tubular degeneration, and oligospermia; no effects on reproductive organs were observed in non-human primates.
